News | ACC | February 29, 2024

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

Five highly anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA.

Five highly-anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA.

Five highly anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA. Image courtesy: ACC


February 29, 2024 — The American College of Cardiology (ACC) will soon be holding its ACC 73rd Annual Scientific Session & Expo, ACC.24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center. This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly anticipated clinical trials. According to ACC, five Late-Breaking Clinical Trial sessions, two LBCT Deep Dive sessions, three Featured Clinical Research sessions, and the Clinical and an Investigative Horizons session will be presented throughout the Scientific Sessions this year.

In addition, the ACC notes that 2024 marks the 40th Anniversary of American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines. According to the program schedule, ACC members in attendance will be able to learn how to implement, optimize, and translate guidelines into your clinical practice from key members of the guideline committees and experienced colleagues. The Guidelines Sessions at ACC.24 will focus on the following three current guideline updates:

American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines

2023 Atrial Fibrillation Guideline

- Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? (Session 104)

- What Is Really New in Electrophysiology That Will Change My Practice? Joint Symposium of the Heart Rhythm Society and the American College of Cardiology (Session 611)

- Newer Strategies in AF Management: From Prediction to Prevention and Treatment (Session 624)

2022 Aortic Disease Guideline

The Aorta Strikes Back: Adventures in Aortopathies (Session 686)

2020 Valvular Heart Disease Guideline

- Dilemmas in the Lifetime Management of Aortic Stenosis (Session 682)

- 2024: A Valve Odyssey (Session 678)

- Heart and Soul: Utilizing Guidelines and Clinical Pathways in the Care of Valve Patients (Session 756)

Late-breaking Science Sessions

What follows is the listing of late-breaking science sessions to be presented during ACC.24:

Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402)

Saturday, April 6
9:30 – 10:30 a.m. ET
Main Tent (Hall B1)

- A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial

- Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial

- CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute Myocardial Infarction (ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

Featured Clinical Research I (Session 403)

Saturday, April 6
4:15 – 5:30 p.m. ET
Murphy Ballroom 4

Late-Breaking Clinical Trials II (Session 405)

Sunday, April 7
8 – 9:15 a.m. ET
Main Tent (Hall B1)

Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials III (Session 406)

Sunday, April 7
9:45 – 11 a.m. ET
Main Tent (Hall B1)

  • Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients with Small Aortic Annuli: Primary Outcomes from the Randomized Smart Trial
  • Effect of Edetate Disodium Based Chelation Infusions on Cardiovascular Events in Post-MI Patients with Diabetes: The TACT2 Trial
  • Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction: The REDUCE-AMI Trial
  • Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock: Results of the Danger-shock Trial
  • One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes: Principal Results From the Double-blind, Placebo-controlled Ultimate DAPT Trial

Featured Clinical Research II (Session 407)

Sunday, April 7
12:15 – 1:30 p.m. ET
Main Tent (Hall B1)

  • Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium (B-Free): A Multi-centre Randomized Cluster Crossover Trial
  • The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Study: A Randomized Evaluation of a Team-based Remote Education and Medication Management Program to Reduce CV and Kidney Risk
  • Improving Cardiac Rehabilitation Participation in Lower-socioeconomic Status Patients: Case Management Vs. Financial Incentives
  • Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic (PRO-HF) Trial
  • Restrictive Versus Liberal Blood Transfusion Strategy in Type 1 Versus Type 2 Myocardial Infarction: A Prespecified Subgroup Analysis from the Myocardial Ischemia and Transfusion (MINT) Trial

Late-Breaking Clinical Trials Deep Dive I (Session 408)

Sunday, April 7
2 – 3:15 p.m. ET
Main Tent (Hall B1)

This session offers more insights from key clinical trials presented at ACC.24 and find out what it all means for your patients.

Clinical and Investigative Horizons (Session 410)

Sunday, April 7
4:30 – 5:45 p.m. ET
Murphy Ballroom 4

  • Health 360x Registry: Scalable Workforce for Equitable Access to Point of Care Decentralized Clinical Trials
  • Prevalence of Cardiovascular Disease and Risk Factors Among National Football League Alumni and Their Family Members: Results from the Huddle Study
  • Hózhó (Heart Failure Optimization at Home to Improve Outcomes): A Pragmatic Clinical Trial of Telephone-based Guideline-directed Medical Therapy Optimization in Navajo Nation
  • Advancing Acute MI Care in Densely Populated LMICs: Innovative Standalone Chest Pain Units For Expedited Triage and Timely Management – A Role Model For Global Healthcare Systems
  • A Clinical Trial to Evaluate the Influence of a Spirituality Intervention on Blood Pressure Control, Central Hemodynamics and Endothelial Function: The Feel Trial

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV (Session 411)

Monday, April 8
8:30 – 9:45 a.m. ET
Main Tent (Hall B1)

  • A Selective Aldose Reductase Inhibitor (at-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
  • Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results of IMPROVE-HCM
  • Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery
  • Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced Cardiotoxicity (PROACT)
  • Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

Late-Breaking Clinical Trials V (Session 412)

Monday, April 8
11 a.m. – 12:15 p.m. ET
Main Tent (Hall B1)

  • Coronary Sinus Reducer for the Treatment of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)
  • Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk: One Year Outcomes of the Randomized DEDICATE-DZHK6 Trial
  • Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results from the Target Bp I Randomized Trial
  • Preventive PCI or Medical Therapy Alone for Atherosclerotic Coronary Vulnerable Plaques
  • Comparison of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty for the Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease

Featured Clinical Research III (Session 413)

Monday, April 8
12:45 – 2 p.m. ET
Room B406A

  • Fractional Flow Reserve-guided Complete or Culprit-only PCI in Patients With ST-elevation Myocardial Infarction
  • A Multicenter Prospective Randomized Study Comparing the Incidence of Periprocedural Cerebral Embolisms Caused by Catheter Ablation of Atrial Fibrillation Between Cryoballoon and Radiofrequency Ablation
  • Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (the TRAVERSE Trial)
  • Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, IVUS-ACS Trial
  • Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial

Late-Breaking Clinical Trials Deep Dive II (Session 414)

Monday, April 8
2:30 – 3:45 p.m. ET
Murphy Ballroom 4

ACC.24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 and how those may impact clinical practice and patient care in this deep dive clinical trial session.

More information: www.acc.org

Find more ACC24 conference coverage here


Related Content

News | Cardiovascular Education

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports ...

Home May 31, 2024
Home
News | Cardiovascular Education

April 25, 2024 —Heart-Valve-Surgery.com, a leading patient advocacy group for heart valve disease, with support from ...

Home April 25, 2024
Home
News | Cardiovascular Education

March 21, 2024 — The UCLA Department of Medicine has announced that Priscilla Hsue, MD will be joining as the chief of ...

Home March 21, 2024
Home
Feature | Cardiovascular Education | Christine Book

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

Home February 01, 2024
Home
News | Cardiovascular Education

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the ...

Home January 15, 2024
Home
News | Cardiovascular Education

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

Home December 04, 2023
Home
News | Cardiovascular Education

October 5, 2023 — The 2023 American College of Cardiology (ACC) Quality Summit kicks off on October 11-13 in Orlando ...

Home October 05, 2023
Home
News | Cardiovascular Education

DAIC’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Home August 16, 2023
Home
Feature | Cardiovascular Education | Christine Book

May 4, 2023 — A new book on a broad collection of cases, led by a team of investigators from the Smidt Heart Institute ...

Home May 04, 2023
Home
News | Cardiovascular Education

April 10, 2023 — Viatris Inc., a global healthcare company, and the American College of Cardiology (ACC) today released ...

Home April 10, 2023
Home
Subscribe Now